CLLS — Cellectis S.A.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1627281 ·
France
Last close
$1.25
Market Cap
$90.90M
52W High
$5.48
52W Low
$1.22
ADV30
150,954
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 5,229,000 | 2,874,000 | -23,520,000 | -21,819,000 | 267,365,000 | 35,590,000 | 226,298,000 |
| Mar 2026 | 5,777,000 | 3,457,000 | -25,168,000 | -17,765,000 | 289,187,000 | 34,841,000 | 229,267,000 |
| Dec 2025 | 10,396,000 | 7,397,000 | -17,351,000 | -26,318,000 | 324,720,000 | 61,533,000 | 248,819,000 |
| Sep 2025 | 35,172,000 | 32,815,000 | 8,041,000 | 589,000 | 343,045,000 | 52,243,000 | 242,567,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-37,654,000
Investing CF
$-39,871,000
Financing CF
$-17,570,000
CapEx
$-3,403,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.61
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-351,939,000
Inventory
—
Receivables
$15,050,000
ST Investments
$150,822,000
EBIT TTM
$-59,484,000
Pretax Income TTM
$-67,608,000
Interest Exp TTM
$8,124,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$63,823,000
EBITDA
$-46,677,000
Free Cash Flow
$107,701,376
Enterprise Value
$139,028,288
Total Cash
$166,686,000
Total Debt
$80,350,000
Shares Out
72,718,974
Trailing EPS
$-0.64
Book Value
$0.56
ROE
-94.5%
ROA
-11.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 72,949,000 | -33,076,000 | -67,593,000 | 324,720,000 | 248,819,000 | 75,901,000 | -39,401,000 |
| Dec 2024 | 41,506,000 | -59,554,000 | -36,761,000 | 383,544,000 | 252,511,000 | 131,033,000 | 22,989,000 |
| Dec 2023 | 755,000 | -97,303,000 | -101,059,000 | 334,270,000 | 249,575,000 | 84,695,000 | -24,746,000 |
| Dec 2022 | 19,171,000 | -89,666,000 | -106,139,000 | 261,216,000 | 135,275,000 | 117,968,000 | -87,444,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.62
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.26 · call volume: 20 · put volume: 0
Expected Move to 2027-02-19:
±$0.57
(45.24%) —
implied range
$0.69 –
$1.83
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NMRA | Neumora Therapeutics, Inc. | $90.15M | $0.48 | — |
| ATRA | Atara Biotherapeutics, Inc. | $92.65M | $9.23 | — |
| CGTX | COGNITION THERAPEUTICS INC | $85.13M | $0.90 | — |
| CRDF | Cardiff Oncology, Inc. | $82.46M | $1.06 | — |
| BDTX | Black Diamond Therapeutics, Inc. | $103.72M | $1.81 | — |
News headlines (Yahoo Finance, 1h cache)
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders
2026-10-01 20:02 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
2026-09-30 15:19 · Yahoo
Cellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?
2026-09-17 05:16 · Yahoo
CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot
2026-09-15 11:11 · Yahoo
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
2026-10-06 15:11 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
2026-09-22 15:19 · Yahoo
European Equities Traded in the US as American Depositary Receipts Drop in Friday Trading
2026-09-18 15:09 · Yahoo
European Equities Traded in US as ADRs Fall in Thursday Trading
2026-10-08 15:05 · Yahoo
European Equities Traded in US as ADRs Fall in Wednesday Trading
2026-10-07 15:09 · Yahoo
Monthly information on share capital and company voting rights
2026-10-06 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.